VXA-GI.1.NN + Placebo Tablet
Phase 1Completed 0 views this week 0 watching💤 Quiet
Interest: 19/100
19
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Norovirus Infections
Conditions
Norovirus Infections
Trial Timeline
Apr 26, 2021 → Jan 4, 2022
NCT ID
NCT04854746About VXA-GI.1.NN + Placebo Tablet
VXA-GI.1.NN + Placebo Tablet is a phase 1 stage product being developed by Vaxart for Norovirus Infections. The current trial status is completed. This product is registered under clinical trial identifier NCT04854746. Target conditions include Norovirus Infections.
What happened to similar drugs?
0 of 1 similar drugs in Norovirus Infections were approved
Approved (0) Terminated (0) Active (1)
Hype Score Breakdown
Clinical
6
Activity
8
Company
5
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04854746 | Phase 1 | Completed |
Competing Products
13 competing products in Norovirus Infections
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| mRNA-1403 | Moderna | Phase 2 | 0 |
| mRNA-1403 | Moderna | Phase 3 | 0 |
| VXA-G1.1-NN + VXA-G2.4-NS + Placebo Tablets | Vaxart | Phase 1 | 19 |
| VXA-G1.1-NN (high dose) Oral Vaccine Tablet + VXA-G1.1-NN (low dose) Oral Vaccine Tablet | Vaxart | Phase 1 | 19 |
| VXA-G1.1-NN + VXA-G2.4-NS + VXA G1.1 NN-T + VXA G2.4 NS-T | Vaxart | Phase 1 | 23 |
| VXA-G1.1-NN | Vaxart | Phase 1/2 | 22 |
| VXA-G1.1-NN Oral Vaccine | Vaxart | Phase 1 | 19 |
| VXA-G1.1-NN | Vaxart | Phase 1 | 19 |
| Norwalk GI.1 Virus | Vaxart | Phase 1 | 19 |
| VXA-G1.1-NN + Norovirus GI.1 Norwalk Virus Inoculum | Vaxart | Phase 1/2 | 22 |
| Open label Bivalent GII.4/GI.1 high dose vaccine 2×10 to the power 11 IU/dose + Bivalent GII.4/GI.1 high dose vaccine 2×10 to the power 11 IU/dose + Bivalent GII.4/GI.1 medium dose vaccine 1×10 to the power 11 IU/dose + Placebo | Vaxart | Phase 2 | 25 |
| VXA-G1.1-NN + VXA-G2.4-NS + Placebo Tablets | Vaxart | Phase 1 | 19 |
| CDI-988 + Placebo | Cocrystal Pharma | Phase 1/2 | 29 |